Pareto Securities has notified Isofol Medical AB that stabilisation measures regarding the Company’s shares have been taken
For a complete press release follow the link http://isofol.se/en/ipo/ For additional information, please contact: Anders Rabbe, Managing Director, IsofolMob: +46 70 764 65 00Email: anders.rabbe@isofolmedical.com Jan-Eric Österlund, Executive Chairman, IsofolMob: +44 77 853 68 155Email: jan-eric@osterlund.co.uk About Isofol Medical AB (publ) Isofol is a clinical stage oncology company developing Modufolin® as a first-line treatment of metastatic colorectal cancer and as a rescue drug after high-dose methotrexate treatment in osteosarcoma. Isofol aims to replace the